Atogepant modulates brain connectivity in episodic migraine: a longitudinal exploratory fMRI study.

Episodic migraine (EM) is a common and debilitating condition affecting many people. Recent treatments have focused on a substance called CGRP, which plays a role in migraines. Atogepant is a new oral medication that belongs to a class of drugs called gepants. This study looked at how atogepant affects brain activity and connectivity in patients with EM. Researchers followed a group of patients for 12 weeks while they took atogepant. They used brain scans to observe changes in brain function and neurotransmitter systems. The goal was to understand how this medication might change brain activity related to migraines. This study is important because it helps clarify the effects of atogepant on the brain. Understanding these changes could lead to better treatments for people suffering from episodic migraines in the future. Clinical relevance: This research indicates that atogepant may alter brain connectivity, potentially improving migraine management strategies.